5-[(2R,6S)-2-methyl-6-[[(2S)-2-methyl-3-oxopiperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile
C21H25N5O2 — CID 122504681
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[(2R,6S)-2-methyl-6-[[(2S)-2-methyl-3-oxopiperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile
5-[(2R,6S)-2-methyl-6-[[(2S)-2-methyl-3-oxopiperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile (PubChem CID 122504681) has the molecular formula C21H25N5O2 and a molecular weight of 379.46 g/mol. Its IUPAC name is 5-[(2R,6S)-2-methyl-6-[[(2S)-2-methyl-3-oxopiperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile.
Molecular Properties
| Compound Name | 5-[(2R,6S)-2-methyl-6-[[(2S)-2-methyl-3-oxopiperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile |
|---|---|
| PubChem CID | 122504681 |
| Molecular Formula | C21H25N5O2 |
| Molecular Weight | 379.46 g/mol |
| Exact Mass | 379.20 |
| IUPAC Name | 5-[(2R,6S)-2-methyl-6-[[(2S)-2-methyl-3-oxopiperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile |
| SMILES | C[C@@H]1CN(c2ccc(C#N)c3ncccc23)C[C@H](CN2CCNC(=O)[C@@H]2C)O1 |
| InChI | InChI=1S/C21H25N5O2/c1-14-11-26(13-17(28-14)12-25-9-8-24-21(27)15(25)2)19-6-5-16(10-22)20-18(19)4-3-7-23-20/h3-7,14-15,17H,8-9,11-13H2,1-2H3,(H,24,27)/t14-,15+,17+/m1/s1 |
| InChIKey | KENZMKZRHCGYHW-VYDXJSESSA-N |
| XLogP | 1.52 |
| TPSA | 81.49 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 379.46 |
| LogP ≤ 5 | 1.52 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122504681 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.